Skip to main content

Advertisement

Table 1 Clinical characteristics of 416 NSCLC patients treated with EGFR-TKIs

From: Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

Variables Patients EGFR mutation EGFR copy number
n = 416 Mutant Wild   FISH (+) FISH (−)  
No. % n = 169 n = 247 P value n = 167 n = 249 P value
Age groups
 ≤ 60 264 63.5 108 (63.9) 156 (63.2) 0.918 108 (64.7) 156 (62.7) 0.680
 > 60 152 36.5 61 (36.1) 91 (36.8) 59 (35.3) 93 (37.3)
Gender
 Male 253 60.8 86 (50.9) 167 (67.6) < 0.001 92 (55.1) 161 (64.7) 0.052
 Female 163 39.2 83 (49.1) 80 (32.4) 75 (44.9) 88 (35.3)
Smoking status
 Never-smoker 269 64.7 129 (76.3) 140 (56.7) < 0.001 116 (69.5) 155 (62.2) 0.142
 Smoker 147 35.3 40 (23.7) 107 (43.3) 51 (30.5) 94 (37.8)
Histology
 ADC 336 80.8 154 (91.1) 182 (73.7) < 0.001 138 (82.6) 198 (79.5) 0.449
 Non-ADC 80 19.2 15 (8.9) 65 (26.3) 29 (17.4) 51 (20.5)
Differentiation
 High to medium 185 44.5 92 (54.4) 93 (37.7) < 0.001 85 (50.9) 100 (40.2) 0.035
 Low 231 55.5 77 (45.6) 154 (62.3) 82 (49.1) 149 (59.8)
Disease stage
 Recurrent 128 30.8 55 (32.5) 73 (29.6) 0.127 51 (30.5) 77 (30.9) 0.926
 IIIb 73 17.5 22 (13.0) 51 (20.6) 28 (16.8) 45 (18.1)
 IV 215 51.7 92 (54.4) 123 (49.8) 88 (52.7) 127 (51.0)
Clinical response
 CR + PR 93 22.4 68 (40.2) 25 (10.1) < 0.001 53 (31.7) 40 (16.1) < 0.001
 SD 158 38.0 83 (49.1) 75 (30.4) 79 (47.3) 79 (31.7)
 PD 161 38.7 14 (8.3) 147 (59.5) 32 (19.2) 129 (51.8)
 Unknown 4 1.0 4 (2.4) 0 (0.0) 3 (1.8) 1 (0.4)
Line of EGFR-TKIs
 First 104 25.0 62 (36.7) 42 (17.0) < 0.001 48 (28.7) 56 (22.5) < 0.001
 Second 217 52.2 107 (63.3) 110 (44.5) 97 (58.1) 120 (48.2)
 Higher 95 22.8 0 (0.0) 95 (38.5) 22 (13.2) 73 (29.3)
  1. Non-adenocarcinoma included squamous-cell carcinoma (n = 58), adenosquamous cell carcinoma (n = 20), and other histology (n = 2)
  2. ADC adenocarcinoma, FISH fluorescent in situ hybridization, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, TKI, tyrosine kinase inhibitor